Free Trial
→ URGENT: Someone's Moving Gold Out of London... (From Golden Portfolio) (Ad) Buy ORIC Stock  Free ORIC Stock Alerts

ORIC Pharmaceuticals (ORIC) Financials

ORIC Pharmaceuticals logo
$5.67 +0.10 (+1.80%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$6.00 +0.33 (+5.82%)
As of 04:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for ORIC Pharmaceuticals

Annual Income Statements for ORIC Pharmaceuticals

This table shows ORIC Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -89 -101 -128
Consolidated Net Income / (Loss)		 -89 -101 -128
Net Income / (Loss) Continuing Operations		 -89 -101 -128
Total Pre-Tax Income 		-89 -101 -128
Total Operating Income		 -92 -111 -143
Total Gross Profit		 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00
Total Operating Expenses		 92 111 143
Selling, General & Admin Expense		 25 26 29
Research & Development Expense		 67 85 114
Total Other Income / (Expense), net		 2.65 10 15
Basic Earnings per Share		 ($2.25) ($1.96) ($1.83)
Weighted Average Basic Shares Outstanding		 39.66M 51.45M 69.73M
Diluted Earnings per Share		 ($2.25) ($1.96) ($1.83)
Weighted Average Diluted Shares Outstanding		 39.66M 51.45M 69.73M
Weighted Average Basic & Diluted Shares Outstanding		 45.09M 67.38M 71.03M

Quarterly Income Statements for ORIC Pharmaceuticals

This table shows ORIC Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -25 -21 -24 -23 -25 -28 -25 -32 -34 -37
Consolidated Net Income / (Loss)		 -25 -21 -24 -23 -25 -28 -25 -32 -35 -36
Net Income / (Loss) Continuing Operations		 -25 -21 -24 -23 -25 -28 -25 -32 -35 -36
Total Pre-Tax Income 		-25 -21 -24 -23 -25 -28 -25 -32 -35 -36
Total Operating Income		 -26 -22 -26 -25 -29 -31 -29 -36 -38 -40
Total Operating Expenses		 26 22 26 25 29 31 29 36 38 40
Selling, General & Admin Expense		 5.97 5.82 6.16 6.21 6.29 6.95 7.03 7.08 7.12 7.60
Research & Development Expense		 20 16 20 19 22 24 22 29 31 32
Total Other Income / (Expense), net		 0.87 1.27 1.73 2.05 3.20 3.10 3.98 4.05 3.75 3.26
Basic Earnings per Share		 ($0.63) ($0.52) ($0.53) ($0.50) ($0.44) ($0.49) ($0.37) ($0.45) ($0.49) ($0.52)
Weighted Average Basic Shares Outstanding		 39.58M 39.66M 45.09M 45.65M 57.40M 51.45M 67.35M 70.35M 70.54M 69.73M
Diluted Earnings per Share		 ($0.63) ($0.52) ($0.53) ($0.50) ($0.44) ($0.49) ($0.37) ($0.45) ($0.49) ($0.52)
Weighted Average Diluted Shares Outstanding		 39.58M 39.66M 45.09M 45.65M 57.40M 51.45M 67.35M 70.35M 70.54M 69.73M
Weighted Average Basic & Diluted Shares Outstanding		 39.58M 45.09M 45.09M 54.53M 54.55M 67.38M 67.42M 70.54M 70.57M 71.03M

Annual Cash Flow Statements for ORIC Pharmaceuticals

This table details how cash moves in and out of ORIC Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 -159 -43 36
Net Cash From Operating Activities		 -75 -86 -113
Net Cash From Continuing Operating Activities		 -75 -86 -113
Net Income / (Loss) Continuing Operations		 -89 -101 -128
Consolidated Net Income / (Loss)		 -89 -101 -128
Depreciation Expense		 0.97 1.03 1.11
Amortization Expense		 -1.04 -6.17 -8.10
Non-Cash Adjustments To Reconcile Net Income		 15 15 20
Changes in Operating Assets and Liabilities, net		 -0.45 4.90 1.97
Net Cash From Investing Activities		 -109 -43 22
Net Cash From Continuing Investing Activities		 -109 -43 22
Purchase of Property, Plant & Equipment		 -2.08 -0.85 -1.19
Purchase of Investments		 -238 -239 -252
Sale and/or Maturity of Investments		 131 197 275
Net Cash From Financing Activities		 25 86 127
Net Cash From Continuing Financing Activities		 25 86 127
Repayment of Debt		 -0.40 -0.23 -0.17
Issuance of Common Equity		 26 86 126
Other Financing Activities, net		 0.08 0.06 0.63

Quarterly Cash Flow Statements for ORIC Pharmaceuticals

This table details how cash moves in and out of ORIC Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Change in Cash & Equivalents		 -20 38 -7.85 45 -77 -2.85 33 -6.53 -5.60 15
Net Cash From Operating Activities		 -19 -15 -21 -21 -20 -24 -30 -26 -29 -28
Net Cash From Continuing Operating Activities		 -19 -15 -21 -21 -20 -24 -30 -26 -29 -28
Net Income / (Loss) Continuing Operations		 -25 -21 -24 -23 -25 -28 -25 -32 -35 -36
Consolidated Net Income / (Loss)		 -25 -21 -24 -23 -25 -28 -25 -32 -35 -36
Depreciation Expense		 0.22 0.25 0.25 0.26 0.26 0.26 0.26 0.27 0.27 0.30
Amortization Expense		 -0.37 -0.62 -0.86 -1.26 -1.92 -2.12 -2.23 -2.30 -1.95 -1.63
Non-Cash Adjustments To Reconcile Net Income		 3.29 3.17 3.61 3.83 3.86 3.94 4.96 5.00 5.06 5.20
Changes in Operating Assets and Liabilities, net		 2.37 2.72 0.31 -1.03 3.63 1.98 -8.17 3.37 2.39 4.38
Net Cash From Investing Activities		 -0.69 28 13 -19 -58 21 -62 18 23 43
Net Cash From Continuing Investing Activities		 -0.69 28 13 -19 -58 21 -62 18 23 43
Purchase of Property, Plant & Equipment		 -0.40 -0.29 -0.31 -0.41 -0.08 -0.06 -0.22 -0.33 -0.42 -0.22
Purchase of Investments		 -61 -32 -43 -56 -111 -29 -114 -49 -54 -35
Sale and/or Maturity of Investments		 61 60 56 37 53 50 53 68 78 78
Net Cash From Financing Activities		 0.00 25 0.00 85 0.03 0.45 125 0.82 0.13 0.58
Net Cash From Continuing Financing Activities		 0.00 25 0.00 85 0.03 0.45 125 0.82 0.13 0.58
Issuance of Common Equity		 - 25 0.00 85 - 0.43 125 0.52 - 0.56
Other Financing Activities, net		 0.00 0.00 0.00 - 0.03 0.03 0.20 0.29 0.13 0.01

Annual Balance Sheets for ORIC Pharmaceuticals

This table presents ORIC Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Total Assets		 247 252 274
Total Current Assets		 210 213 262
Cash & Equivalents		 67 23 59
Short-Term Investments		 139 185 197
Prepaid Expenses		 4.19 4.41 6.29
Plant, Property, & Equipment, net		 3.25 2.86 2.92
Total Noncurrent Assets		 33 37 8.97
Long-Term Investments		 22 27 0.00
Other Noncurrent Operating Assets		 12 9.70 8.97
Total Liabilities & Shareholders' Equity		 247 252 274
Total Liabilities		 25 28 31
Total Current Liabilities		 15 20 25
Accounts Payable		 1.32 0.94 1.55
Accrued Expenses		 14 20 23
Total Noncurrent Liabilities		 9.44 7.46 6.17
Other Noncurrent Operating Liabilities		 9.44 7.46 6.17
Commitments & Contingencies		 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 222 224 243
Total Preferred & Common Equity		 222 224 243
Preferred Stock		 0.00 0.00 0.00
Total Common Equity		 222 224 243
Common Stock		 558 659 806
Retained Earnings		 -334 -435 -563
Accumulated Other Comprehensive Income / (Loss)		 -1.29 0.26 0.38

Quarterly Balance Sheets for ORIC Pharmaceuticals

This table presents ORIC Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024
Total Assets		 238 227 292 274 351 329 302
Total Current Assets		 199 193 268 232 324 295 279
Cash & Equivalents		 29 59 104 26 56 50 44
Short-Term Investments		 165 131 160 201 260 237 228
Prepaid Expenses		 5.03 3.54 4.20 4.94 7.31 8.19 7.06
Plant, Property, & Equipment, net		 3.05 3.11 3.25 3.06 2.80 2.88 3.09
Total Noncurrent Assets		 36 30 20 39 24 31 20
Long-Term Investments		 24 19 9.58 29 15 22 10.00
Other Noncurrent Operating Assets		 12 11 11 10 9.21 9.30 9.55
Total Liabilities & Shareholders' Equity		 238 227 292 274 351 329 302
Total Liabilities		 23 24 23 27 22 27 28
Total Current Liabilities		 13 15 15 19 15 20 21
Accounts Payable		 1.53 1.93 3.19 3.74 2.99 2.31 4.25
Accrued Expenses		 12 13 11 15 12 17 17
Total Noncurrent Liabilities		 9.89 8.97 8.48 7.98 6.93 6.97 6.83
Other Noncurrent Operating Liabilities		 9.89 8.97 8.48 7.98 6.93 6.97 6.83
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 215 203 269 247 329 302 274
Total Preferred & Common Equity		 215 203 269 247 329 302 274
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 215 203 269 247 329 302 274
Common Stock		 530 561 650 654 789 795 800
Retained Earnings		 -313 -358 -381 -407 -460 -492 -526
Accumulated Other Comprehensive Income / (Loss)		 -1.75 -0.50 -0.57 -0.37 -0.16 -0.26 0.72

Annual Metrics and Ratios for ORIC Pharmaceuticals

This table displays calculated financial ratios and metrics derived from ORIC Pharmaceuticals' official financial filings.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - -
Revenue Growth		 0.00% 0.00% 0.00%
EBITDA Growth		 -19.88% -26.21% -29.31%
EBIT Growth		 -16.37% -20.72% -28.99%
NOPAT Growth		 -16.35% -20.72% -28.99%
Net Income Growth		 -13.22% -12.99% -26.96%
EPS Growth		 -8.70% 12.89% 6.63%
Operating Cash Flow Growth		 -26.20% -14.03% -31.48%
Free Cash Flow Firm Growth		 -27.32% -10.21% -35.43%
Invested Capital Growth		 20.53% -86.50% -17.23%
Revenue Q/Q Growth		 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -0.07% -10.27% -5.35%
EBIT Q/Q Growth		 0.74% -9.17% -6.04%
NOPAT Q/Q Growth		 0.74% -9.17% -6.04%
Net Income Q/Q Growth		 2.11% -8.03% -6.65%
EPS Q/Q Growth		 2.60% 1.51% -1.67%
Operating Cash Flow Q/Q Growth		 1.26% -11.65% -3.48%
Free Cash Flow Firm Q/Q Growth		 1.13% -10.75% -3.63%
Invested Capital Q/Q Growth		 -86.41% -25.17% -53.33%
Profitability Metrics		 - - -
Gross Margin		 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00%
Interest Burden Percent		 97.12% 90.90% 89.47%
Effective Tax Rate		 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -35.99% -45.11% -54.73%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -35.99% -45.11% -54.73%
Return on Equity Simple (ROE_SIMPLE)		 -40.08% -44.94% -52.59%
Net Operating Profit after Tax (NOPAT)		 -64 -78 -100
NOPAT Margin		 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -9.79% -9.99% -11.33%
Return On Investment Capital (ROIC_SIMPLE)		 - -34.61% -41.14%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -92 -111 -143
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -92 -116 -150
Valuation Ratios		 - - -
Price to Book Value (P/BV)		 1.05 2.24 2.34
Price to Tangible Book Value (P/TBV)		 1.05 2.24 2.34
Price to Revenue (P/Rev)		 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00
Leverage & Solvency		 - - -
Debt to Equity		 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00
Financial Leverage		 -1.03 -1.04 -1.05
Leverage Ratio		 1.10 1.12 1.13
Compound Leverage Factor		 1.07 1.02 1.01
Debt to Total Capital		 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00
Altman Z-Score		 3.46 7.83 7.46
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00%
Liquidity Ratios		 - - -
Current Ratio		 13.68 10.39 10.56
Quick Ratio		 13.40 10.18 10.30
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 -66 -72 -98
Operating Cash Flow to CapEx		 -3,616.12% -10,092.82% -9,483.33%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00
Efficiency Ratios		 - - -
Asset Turnover		 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00
Capital & Investment Metrics		 - - -
Invested Capital		 -5.87 -11 -13
Invested Capital Turnover		 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 1.52 -5.08 -1.89
Enterprise Value (EV)		 4.88 267 314
Market Capitalization		 233 502 569
Book Value per Share		 $5.62 $4.11 $3.45
Tangible Book Value per Share		 $5.62 $4.11 $3.45
Total Capital		 222 224 243
Total Debt		 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00
Net Debt		 -228 -235 -256
Capital Expenditures (CapEx)		 2.08 0.85 1.19
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -11 -16 -19
Debt-free Net Working Capital (DFNWC)		 195 192 237
Net Working Capital (NWC)		 195 192 237
Net Nonoperating Expense (NNE)		 25 23 28
Net Nonoperating Obligations (NNO)		 -228 -235 -256
Total Depreciation and Amortization (D&A)		 -0.08 -5.14 -7.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 ($2.25) ($1.96) ($1.83)
Adjusted Weighted Average Basic Shares Outstanding		 39.66M 51.45M 69.73M
Adjusted Diluted Earnings per Share		 ($2.25) ($1.96) ($1.83)
Adjusted Weighted Average Diluted Shares Outstanding		 39.66M 51.45M 69.73M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 45.09M 67.38M 71.03M
Normalized Net Operating Profit after Tax (NOPAT)		 -64 -78 -100
Normalized NOPAT Margin		 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00%
Debt Service Ratios		 - - -
EBIT to Interest Expense		 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00
Payout Ratios		 - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00%

Quarterly Metrics and Ratios for ORIC Pharmaceuticals

This table displays calculated financial ratios and metrics derived from ORIC Pharmaceuticals' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -44.31% -0.29% -14.46% -26.54% -17.43% -48.00% -17.77% -46.33% -31.79% -22.87%
EBIT Growth		 -39.22% 3.01% -10.41% -20.76% -11.63% -42.09% -12.90% -44.11% -33.60% -25.91%
NOPAT Growth		 -39.22% 3.01% -10.41% -20.76% -11.63% -42.09% -12.90% -44.11% -33.60% -25.91%
Net Income Growth		 -34.75% 8.45% -3.39% -13.10% -2.61% -35.89% -4.45% -39.31% -35.67% -28.16%
EPS Growth		 -34.04% 10.34% 10.17% 1.96% 30.16% 5.77% 30.19% 10.00% -11.36% -6.12%
Operating Cash Flow Growth		 -59.12% 5.86% 9.20% -18.95% -1.68% -58.33% -46.34% -21.19% -46.59% -15.59%
Free Cash Flow Firm Growth		 -93.58% -37.12% 1.69% 16.85% 26.78% 0.47% -57.61% -77.55% -87.86% -52.55%
Invested Capital Growth		 36.22% 20.53% -96.35% -410.87% -177.75% -86.50% 53.85% -24.26% 4.30% -17.23%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -25.80% 12.97% -16.87% 1.10% -16.74% -9.69% 7.01% -22.89% -5.13% -2.27%
EBIT Q/Q Growth		 -24.15% 13.91% -16.09% 2.67% -14.76% -9.57% 7.76% -24.24% -6.39% -3.27%
NOPAT Q/Q Growth		 -24.15% 13.91% -16.09% 2.67% -14.76% -9.57% 7.76% -24.24% -6.39% -3.27%
Net Income Q/Q Growth		 -22.39% 16.04% -14.86% 4.18% -11.04% -11.19% 11.72% -27.80% -8.14% -5.04%
EPS Q/Q Growth		 -23.53% 17.46% -1.92% 5.66% 12.00% -11.36% 24.49% -21.62% -8.89% -6.12%
Operating Cash Flow Q/Q Growth		 -8.69% 20.66% -34.57% -2.51% 7.09% -23.54% -24.38% 15.11% -12.38% 2.58%
Free Cash Flow Firm Q/Q Growth		 -21.57% 14.03% 11.95% 9.64% -7.05% -16.87% -39.43% -1.79% -13.26% 5.10%
Invested Capital Q/Q Growth		 -226.09% -86.41% -4.33% 19.44% -77.28% -25.17% 74.19% -116.91% -36.55% -53.33%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 96.63% 94.25% 93.25% 91.81% 88.83% 90.14% 86.27% 88.74% 90.21% 91.75%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -35.96% -35.99% -39.44% -36.61% -40.33% -45.11% -38.30% -38.79% -45.98% -54.73%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -35.96% -35.99% -39.44% -36.61% -40.33% -45.11% -38.30% -38.79% -45.98% -54.73%
Return on Equity Simple (ROE_SIMPLE)		 -42.38% 0.00% -44.33% -34.44% -37.68% 0.00% -30.96% -36.63% -43.75% 0.00%
Net Operating Profit after Tax (NOPAT)		 -18 -15 -18 -17 -20 -22 -20 -25 -27 -28
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -2.66% -2.11% -2.57% -2.13% -2.28% -2.73% -1.75% -2.32% -2.88% -3.51%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - -9.82% - - - -11.39%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -26 -22 -26 -25 -29 -31 -29 -36 -38 -40
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -26 -22 -26 -26 -30 -33 -31 -38 -40 -41
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.59 1.05 1.27 1.30 1.33 2.24 2.82 1.58 2.64 2.34
Price to Tangible Book Value (P/TBV)		 0.59 1.05 1.27 1.30 1.33 2.24 2.82 1.58 2.64 2.34
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.02 -1.03 -1.02 -1.01 -1.03 -1.04 -1.02 -1.02 -1.03 -1.05
Leverage Ratio		 1.09 1.10 1.10 1.09 1.11 1.12 1.09 1.09 1.11 1.13
Compound Leverage Factor		 1.05 1.04 1.03 1.00 0.98 1.01 0.94 0.96 1.00 1.03
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 2.01 4.39 4.83 8.05 5.87 8.87 24.05 9.34 13.62 8.70
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 14.96 13.68 12.99 18.46 12.26 10.39 21.31 15.08 13.15 10.56
Quick Ratio		 14.58 13.40 12.76 18.18 12.00 10.18 20.83 14.66 12.82 10.30
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -20 -17 -15 -14 -14 -17 -24 -24 -27 -26
Operating Cash Flow to CapEx		 -4,817.96% -5,341.12% -6,654.19% -5,220.99% -25,512.99% -42,578.95% -13,846.79% -7,695.20% -6,889.23% -12,810.05%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 -3.15 -5.87 -6.13 -4.94 -8.75 -11 -2.83 -6.13 -8.37 -13
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 1.79 1.52 -3.01 -3.97 -5.60 -5.08 3.30 -1.20 0.38 -1.89
Enterprise Value (EV)		 -91 4.88 48 76 74 267 595 168 441 314
Market Capitalization		 127 233 257 350 330 502 926 477 723 569
Book Value per Share		 $5.43 $5.62 $4.50 $5.96 $4.54 $4.11 $4.88 $4.49 $3.88 $3.45
Tangible Book Value per Share		 $5.43 $5.62 $4.50 $5.96 $4.54 $4.11 $4.88 $4.49 $3.88 $3.45
Total Capital		 215 222 203 269 247 224 329 302 274 243
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -218 -228 -209 -274 -256 -235 -331 -309 -282 -256
Capital Expenditures (CapEx)		 0.40 0.29 0.31 0.41 0.08 0.06 0.22 0.33 0.42 0.22
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -8.26 -11 -11 -10 -14 -16 -7.91 -11 -14 -19
Debt-free Net Working Capital (DFNWC)		 185 195 178 254 213 192 309 275 258 237
Net Working Capital (NWC)		 185 195 178 254 213 192 309 275 258 237
Net Nonoperating Expense (NNE)		 6.84 5.36 5.97 5.45 5.40 6.33 4.72 6.75 7.74 8.61
Net Nonoperating Obligations (NNO)		 -218 -228 -209 -274 -256 -235 -331 -309 -282 -256
Total Depreciation and Amortization (D&A)		 -0.15 -0.37 -0.61 -1.00 -1.67 -1.86 -1.97 -2.02 -1.68 -1.33
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.63) ($0.52) ($0.53) ($0.50) ($0.44) ($0.49) ($0.37) ($0.45) ($0.49) ($0.52)
Adjusted Weighted Average Basic Shares Outstanding		 39.58M 39.66M 45.09M 45.65M 57.40M 51.45M 67.35M 70.35M 70.54M 69.73M
Adjusted Diluted Earnings per Share		 ($0.63) ($0.52) ($0.53) ($0.50) ($0.44) ($0.49) ($0.37) ($0.45) ($0.49) ($0.52)
Adjusted Weighted Average Diluted Shares Outstanding		 39.58M 39.66M 45.09M 45.65M 57.40M 51.45M 67.35M 70.35M 70.54M 69.73M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 39.58M 45.09M 45.09M 54.53M 54.55M 67.38M 67.42M 70.54M 70.57M 71.03M
Normalized Net Operating Profit after Tax (NOPAT)		 -18 -15 -18 -17 -20 -22 -20 -25 -27 -28
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About ORIC Pharmaceuticals' Financials

When does ORIC Pharmaceuticals's financial year end?

According to the most recent income statement we have on file, ORIC Pharmaceuticals' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has ORIC Pharmaceuticals' net income changed over the last 2 years?

ORIC Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$127.85 million in 2024, rising from -$89.12 million in 2022. The previous period was -$100.70 million in 2023. Check out ORIC Pharmaceuticals' forecast to explore projected trends and price targets.

What is ORIC Pharmaceuticals's operating income?
ORIC Pharmaceuticals's total operating income in 2024 was -$142.90 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $142.90 million
How has ORIC Pharmaceuticals revenue changed over the last 2 years?

Over the last 2 years, ORIC Pharmaceuticals' total revenue changed from $0.00 in 2022 to $0.00 in 2024, a change of 0.0%.

How much debt does ORIC Pharmaceuticals have?

ORIC Pharmaceuticals' total liabilities were at $31.02 million at the end of 2024, a 11.1% increase from 2023, and a 24.9% increase since 2022.

How much cash does ORIC Pharmaceuticals have?

In the past 2 years, ORIC Pharmaceuticals' cash and equivalents has ranged from $23.38 million in 2023 to $66.84 million in 2022, and is currently $59.41 million as of their latest financial filing in 2024.

How has ORIC Pharmaceuticals' book value per share changed over the last 2 years?

Over the last 2 years, ORIC Pharmaceuticals' book value per share changed from 5.62 in 2022 to 3.45 in 2024, a change of -38.7%.


Related Companies

This page (NASDAQ:ORIC) was last updated on 5/5/2025 by MarketBeat.com Staff
From Our Partners
Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...
Altimetry | Sponsored
Shocking AI play that’s beats Nvidia by a country mile
You’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...
Timothy Sykes | Sponsored
Gold Alert: The Truth About Fort Knox Is Coming
Owning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...
Golden Portfolio | Sponsored
Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...
Porter & Company | Sponsored
How to invest in Elon Musk’s Optimus before its launch
Elon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...
InvestorPlace | Sponsored
U.S. Stock Market Now on Verge of Collapse
The last time the U.S. economy looked like this, stocks didn't move for 16 years... And many investors lost...
Stansberry Research | Sponsored
Trump announcement boosts “next Bitcoin”
President Trump just made his first big crypto move ... Announcing the creation of a national strategic re...
Weiss Ratings | Sponsored
Altucher: Turn $900 into $108,000 in just 12 months?
We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.
Paradigm Press | Sponsored